Sotalol Monograph: Class II/III Antiarrhythmic Effects, QT Monitoring and Renal Dosing

Evidence-informed pharmacology monograph, updated 10 November 2026. For medical education; individual management requires current product labeling and qualified clinical assessment.

Overview

Sotalol is a nonselective beta-adrenoceptor antagonist with class III antiarrhythmic effects due to inhibition of the rapid delayed rectifier potassium current (IKr). It can suppress selected serious ventricular arrhythmias and maintain sinus rhythm in appropriately selected patients with atrial fibrillation/flutter, but does not provide a general survival advantage and can cause life-threatening proarrhythmia [1,2].

Mechanism and electrophysiology

Beta-1 and beta-2 blockade slows sinus rate and AV-nodal conduction; IKr inhibition prolongs ventricular action potential duration, effective refractory period and QT interval. This does not imply that plasma drug half-life directly determines action-potential duration: the earlier monograph’s elimination equation is a pharmacokinetic model, not a model of repolarization. At slower heart rates, reverse-use dependence can increase QT prolongation and torsades susceptibility [1].

Clinical indications and drug selection

In selected patients, sotalol may help maintain sinus rhythm after conversion of symptomatic atrial fibrillation/flutter. Alternatives such as catheter ablation or other antiarrhythmics may be preferable depending on heart failure, prior infarction, structural disease and QT risk. It may treat serious ventricular tachyarrhythmias in specialist care; routine use for asymptomatic premature ventricular contractions is inappropriate. The risk-benefit decision is individualized [1,2].

2026 boxed warning and initiation requirements

Current US labeling carries a boxed warning for potentially fatal ventricular tachycardia associated with QT prolongation. Initiation or reinitiation of oral sotalol generally requires a facility with continuous ECG monitoring, cardiac resuscitation capability and observation for at least three days or until steady-state exposure. If QT reaches 500 milliseconds or more, the label directs dose reduction, interval extension or discontinuation. Baseline ECG, potassium, magnesium and creatinine clearance assessment must precede treatment [2].

Pharmacokinetics and kidney function

Sotalol has high oral bioavailability and undergoes little metabolism; renal excretion of unchanged drug is important. Its elimination half-life is often about 12 hours with normal kidney function, and prolongs with impairment. The dosing interval is tailored to calculated creatinine clearance and the specific indication; renal-dose guidance for AF differs from some ventricular arrhythmia regimens. It should not be casually prescribed using a uniform twice-daily schedule [1,2].

Risks, interactions and monitoring

Torsades de pointes, bradycardia, hypotension, fatigue and bronchospasm can occur. Avoid or reassess concurrent QT-prolonging drugs, significant hypokalemia or hypomagnesemia, congenital long QT, severe bradyarrhythmias and uncontrolled heart failure. Electrolyte-depleting diuretics, kidney dysfunction and other negative chronotropes increase risk. Repeat ECG and renal monitoring is needed at titration and when clinical status changes [1,2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. DailyMed. Sotalol hydrochloride tablets: prescribing information, boxed warning and renal monitoring. Updated January 28, 2026. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51cebe16-4496-4f49-b2db-b7b21c08fa23
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *